CBD May Reduce Pain Sensitivity Differently Depending on Opioid Treatment Type

In a small proof-of-concept study, CBD improved heat pain tolerance in patients on buprenorphine but not methadone for opioid use disorder, with no serious adverse events at any dose.

Costa, Gabriel P A et al.·Addictive behaviors reports·2026·Preliminary Evidenceclinical-trial
RTHC-08190Clinical TrialPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBD showed a significant interaction with medication type for heat pain measures: buprenorphine patients had significantly higher heat pain threshold (at 400mg CBD) and heat tolerance (at 800mg CBD) compared to methadone patients. The 400mg dose showed the most favorable pain response pattern in the buprenorphine group. CBD was well-tolerated at all doses (400-1200mg).

Key Numbers

7 participants. 3 CBD doses tested: 400mg, 800mg, 1200mg. Significant MOUD×CBD dose interaction for heat pain threshold and tolerance. 400mg CBD showed best response in buprenorphine group. No serious adverse events at any dose. No cognitive effects on verbal memory.

How They Did This

Open-label, proof-of-concept study with 7 individuals receiving methadone or buprenorphine for opioid use disorder with chronic pain. Three test sessions with ascending oral CBD doses (400mg, 800mg, 1200mg). Quantitative sensory testing (QST) used to assess pain sensitivity. Safety and tolerability monitored.

Why This Research Matters

Pain management in opioid use disorder patients is extremely challenging — they need pain relief but are vulnerable to opioid misuse. CBD could offer a non-opioid option, and this study suggests it may work especially well alongside buprenorphine treatment.

The Bigger Picture

The opioid crisis has created urgent need for non-addictive pain treatments, especially for people already struggling with opioid use disorder. The finding that CBD's effects depend on which opioid medication someone takes could personalize pain management approaches.

What This Study Doesn't Tell Us

Extremely small sample (n=7). Open-label design (no placebo control). Cannot generalize from so few participants. Ascending dose design means order effects can't be separated from dose effects. Short-term testing only.

Questions This Raises

  • ?Why does CBD appear to work differently with buprenorphine vs. methadone?
  • ?Would a larger placebo-controlled trial confirm these findings?
  • ?What is the optimal CBD dose for pain management in OUD patients?

Trust & Context

Key Stat:
Evidence Grade:
Very small open-label proof-of-concept (n=7) — hypothesis-generating only, not sufficient for clinical recommendations.
Study Age:
Published in 2026, addressing a critical gap in non-opioid pain management for addiction patients.
Original Title:
Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.
Published In:
Addictive behaviors reports, 23, 100654 (2026)
Database ID:
RTHC-08190

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Could CBD help with pain in people recovering from opioid addiction?

This tiny pilot study (7 people) found promising signals that CBD may improve pain tolerance specifically in patients taking buprenorphine for opioid use disorder. However, much larger trials are needed before any clinical recommendations.

Is CBD safe to take with opioid treatment medications?

In this study, CBD up to 1200mg was well-tolerated alongside both methadone and buprenorphine, with no serious adverse events or cognitive effects. However, the sample was very small, and patients should always consult their provider.

Read More on RethinkTHC

Cite This Study

RTHC-08190·https://rethinkthc.com/research/RTHC-08190

APA

Costa, Gabriel P A; Suh, Rebecca; Sofuoglu, Mehmet; De Aquino, Joao P. (2026). Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.. Addictive behaviors reports, 23, 100654. https://doi.org/10.1016/j.abrep.2025.100654

MLA

Costa, Gabriel P A, et al. "Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.." Addictive behaviors reports, 2026. https://doi.org/10.1016/j.abrep.2025.100654

RethinkTHC

RethinkTHC Research Database. "Exploring the effects of cannabidiol on pain sensitivity usi..." RTHC-08190. Retrieved from https://rethinkthc.com/research/costa-2026-exploring-the-effects-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.